CSF2 and myxofibrosarcoma: In vitro, genetic ablations of PAK1 and CSF2, the CSF2-directed antibody, and pharmacological intervention with PF-3758309 inhibitor all significantly abrogated angiogenesis of myxofibrosarcoma.